New options and old dilemmas in the treatment of patients with advanced colorectal cancer

被引：93

作者：

Punt, CJA ^{[1
]}

机构：

[1] Radboud Univ Nijmegen Med Ctr, Dept Med Oncol, NL-6500 HB Nijmegen, Netherlands

来源：

ANNALS OF ONCOLOGY | 2004年 / 15卷 / 10期

关键词：

bevacizumab; capecitabine; cetuximab; colorectal cancer; irinotecan; oxaliplatin;

D O I：

10.1093/annonc/mdh383

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

With more data on the use of oxaliplatin and irinotecan available, and the recent approval of two signal transduction inhibitors for patients with advanced colorectal cancer, there are now many treatment options to choose from. From the current regimens no straightforward choice can be made that provides any patient with the optimal chance for prolonged survival with the least side-effects. The current data concerning timing and duration of chemotherapy, combination or sequential therapy, preference of agents for first-line treatment, oral fluoropyrimidines, neo-adjuvant chemotherapy for irresectable liver metastases, and the use of signal transduction inhibitors are reviewed.

引用

页码：1453 / 1459

页数：7

共 50 条

[1]

ACKLAND SP, 2001, P AN M AM SOC CLIN, V20, pA132

[2] Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases [J].

Adam, R .

ANNALS OF ONCOLOGY, 2003, 14 :13-16

[3]

Andre T, 2003, P AN M AM SOC CLIN, V22, P253

[4]

[Anonymous], 2003, LANCET, V361, P2167

[5] Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer [J].

Borner, MM ;

Dietrich, D ;

Stupp, R ;

Moran, R ;

Honegger, H ;

Wernli, M ;

Herrmann, R ;

Pestalozzi, BC ;

Saletti, P ;

Hanselmann, S ;

Müller, S ;

Brauchli, P ;

Castiglione-Gertsch, M ;

Goldhirsch, A ;

Roth, AD .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (07) :1759-1766

[6] Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin:: a randomised crossover trial in advanced colorectal cancer [J].

Borner, MM ;

Schöffski, P ;

de Wit, R ;

Caponigro, F ;

Comella, G ;

Sulkes, A ;

Greim, G ;

Peters, GJ ;

van der Born, K ;

Wanders, J ;

de Boer, RF ;

Martin, C ;

Fumoleau, P .

EUROPEAN JOURNAL OF CANCER, 2002, 38 (03) :349-358

[7]

Camps C, 1990, An Med Interna, V7, P525

[8] Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer [J].

Carmichael, J ;

Popiela, T ;

Radstone, D ;

Falk, S ;

Borner, M ;

Oza, A ;

Skovsgaard, T ;

Munier, S ;

Martin, C .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) :3617-3627

[9] First-line oral capecitabine therapy in metastatic colorectal cancer:: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin [J].

Cassidy, J ;

Twelves, C ;

Van Cutsem, E ;

Hoff, P ;

Bajetta, E ;

Boyer, M ;

Bugat, R ;

Burger, U ;

Garin, A ;

Graeven, U ;

McKendrick, J ;

Maroun, J ;

Marshall, J ;

Osterwalder, B ;

Pérez-Manga, G ;

Rosso, R ;

Rougier, P ;

Schilsky, RL .

ANNALS OF ONCOLOGY, 2002, 13 (04) :566-575

[10]

Colorectal Canc Collaborative Grp, 2000, BMJ-BRIT MED J, V321, P531

← 1 2 3 4 5 →